Status:
ENROLLING_BY_INVITATION
Treatment for Social Cognition Disorders (T-ScEmo) in Patients With Acquired Brain Injury and Comorbid Neuropsychiatric Problems
Lead Sponsor:
Ggz Oost Brabant
Collaborating Sponsors:
Maastricht University
UMC Groningen, Groningen, the Netherlands
Conditions:
Acquired Brain Injury
Neuropsychiatric Symptoms
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Acquired brain injury (ABI) can lead to a wide range of physical, cognitive, emotional, and social problems. In the recent years, more research has been conducted to examine the impact of ABI on socia...
Eligibility Criteria
Inclusion
- All patients:
- have an established and documented history of ABI and current neuropsychiatric problems. When patients are referred to our institution, a team of clinical neuropsychologists, psychiatrists, and a high-educated nurse estimate whether patients meet these criteria by using a transdiagnostic tool.
- have social cognition problems. These impairments in social cognition are established by defective scores on the Facial Expression of Emotion-Stimuli and Tests (FEEST) and/or (if available) frontal lesions visible on computed tomographic scan/magnetic resonance image, indicating higher risk on social behavioral problems. The FEEST is already used in standard care.
- are at least 6 months post-injury to avoid the effects of spontaneous recovery.
- are between 18 and 70 years.
- have a significant other/proxy to fill in questionnaires and participate in the treatment. A life partner (persons living together in an intimate relationship, either married or unmarried) is preferred. When patients don't have a life partner, they are asked to bring an adult proxy (a close friend or family member) with whom they have frequent contact in daily life, preferably someone who already knew the patient from before the ABI.
Exclusion
- not being able to receive the T-ScEmo treatment, for example due to severe cognitive impairment
- not speaking the Dutch language.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06923683
Start Date
January 1 2025
End Date
December 1 2027
Last Update
April 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GGZ Oost Brabant
Boekel, North Brabant, Netherlands, 5427EM